Cantor Fitzgerald Reaffirms Overweight Rating for Bioventus (NASDAQ:BVS)

Bioventus (NASDAQ:BVS)‘s stock had its “overweight” rating reiterated by research analysts at Cantor Fitzgerald in a report issued on Monday,Benzinga reports. They presently have a $15.00 price target on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 5.19% from the company’s previous close.

BVS has been the subject of several other research reports. Barrington Research set a $18.00 target price on Bioventus in a research note on Thursday, August 6th. Weiss Ratings raised Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, August 6th. Canaccord Genuity Group reiterated a “buy” rating and set a $15.00 price target on shares of Bioventus in a report on Tuesday, June 16th. Finally, Craig Hallum restated a “buy” rating and issued a $18.00 price objective on shares of Bioventus in a report on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Bioventus Price Performance

Bioventus stock opened at $14.26 on Monday. The company has a current ratio of 1.69, a quick ratio of 1.17 and a debt-to-equity ratio of 0.83. The company has a 50-day moving average price of $11.36 and a 200 day moving average price of $9.91. Bioventus has a 12-month low of $6.26 and a 12-month high of $15.89. The stock has a market cap of $1.20 billion, a P/E ratio of 18.52, a PEG ratio of 1.82 and a beta of 0.63.

Bioventus (NASDAQ:BVS) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.22 EPS for the quarter, meeting the consensus estimate of $0.22. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. The firm had revenue of $153.21 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Sell-side analysts anticipate that Bioventus will post 0.79 earnings per share for the current year.

Institutional Investors Weigh In On Bioventus

A number of hedge funds and other institutional investors have recently modified their holdings of BVS. Caitong International Asset Management Co. Ltd grew its stake in shares of Bioventus by 17,156.2% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock worth $41,000 after purchasing an additional 5,490 shares in the last quarter. Prelude Capital Management LLC acquired a new stake in Bioventus in the third quarter valued at $74,000. Mercer Global Advisors Inc. ADV purchased a new stake in Bioventus during the 3rd quarter worth about $78,000. Brooklyn Investment Group purchased a new stake in Bioventus during the 4th quarter worth about $91,000. Finally, Truist Financial Corp acquired a new position in shares of Bioventus during the 4th quarter worth about $93,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.